Browsing Tag
Pfizer Inc.
21 posts
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
Pfizer just flipped the script on drug prices—now Eli Lilly and Amgen are ripping. Is this the start of a new pharma bull run?
Pfizer’s U.S. drug-pricing pact triggers a pharma relief rally. See what it means for Eli Lilly, Amgen, and investors today—read the data-driven outlook.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
How 3SBio became China’s most watched biotech firm after the Pfizer deal
3SBio is now at the center of global oncology focus after licensing SSGJ-707 to Pfizer. Explore what’s driving its stock surge and strategic ascent.
Pfizer’s $6.05bn bet on oncology innovation: Inside the 3SBio SSGJ-707 licensing deal
Find out how Pfizer’s $6.05B deal with 3SBio could reshape the global cancer immunotherapy market with PD-1/VEGF bispecific SSGJ-707.
Pfizer breakthrough: New immunotherapy combo slashes bladder cancer recurrence risk by 32%
Discover how Pfizer’s new sasanlimab combination therapy is redefining treatment for high-risk bladder cancer after 30 years — read the breakthrough results now!
Haleon to repurchase £170M in shares as Pfizer completes exit
Haleon repurchases £170M in shares as Pfizer exits its stake. Find out how this impacts stock performance, investor sentiment, and future growth.
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.